series-a
Stage
2
Investors
About
Mondego Bio develops selective inhibitors of protein tyrosine phosphatase non-receptor type 2 (PTPN2) to improve the efficacy and safety of cancer immunotherapy by enhancing tumor cell responsiveness to immune signaling.
Explore Mondego Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.